Intracerebral hemorrhage
Conditions
Interventions
Control group:None
Sponsors
The Fifth Affiliated Hospital of Zhengzhou University
Eligibility
Sex/Gender
All
Age
18 Years to 80 Years
Inclusion criteria
Inclusion criteria: 1. Adults aged 18–80 years; 2. Spontaneous intracerebral hemorrhage was documented by CT scanning within 72 hours of the certain time of onset; 3. No planned surgery; 4. Agreed to participate in this study and signed the informed consent.
Exclusion criteria
Exclusion criteria: 1. The hemorrhages were located at brainstem, cerebellar or the ventricles; 2. Secondary causes of ICH, including anticoagulation, thrombolysis or known underlying structural abnormality such as arteriovenous malformation, aneurysm, tumor, or venous thrombosis; 3. Patient with coagulation disorders: hepatitis or thrombocytopenia etc. 4. Patients taking folic acid, vitamin B12, or iron agents; 5. Rebleeding on residual hematoma; 6. Malignant tumor, participation in another clinical trial; 7. Insufficiency of the heart, liver, kidneys and/or lungs. 8. Abnormal thyroid function; 9. Concomitant immune dysfunction or any other autoimmune disease, receiving immune-suppressant medications within 30 days prior to onset; 10. Patients combined with pulmonary infection or urinary tract infections; 11. Antibiotics given within 72 hours of disease onset; 12. Life expectancy less than 3 months; 13. Premorbid handicap: mRS score >3; 14. Other situations judged by the investigators not to be suitable for the clinical trial.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The modified Rankin scale (mRS); | — |
Countries
China
Contacts
Public ContactWang Yali
Department of Neurology, the Fifth Affiliated Hospital of Zhengzhou University
Outcome results
None listed